<DOC>
	<DOCNO>NCT00430105</DOCNO>
	<brief_summary>A comparison intermittent pulse cyclophosphamide daily oral cyclophosphamide treatment ANCA-associated systemic vasculitides kidney involvement . Performed European Vasculitis Study group .</brief_summary>
	<brief_title>Pulse Versus Continuous Cyclophosphamide Induction Remission ANCA-Associated Vasculitides</brief_title>
	<detailed_description>The primary , ANCA-associated systemic vasculitides ( AASV ) , include Wegener ’ granulomatosis microscopic polyangiitis , progressive , multisystem , autoimmune disease respond immunosuppressive therapy . Their treatment corticosteroid cytotoxic drug standardise first wave study ( ECSYSVASTRIAL project ) , limitation regimens include partial efficacy appreciable treatment-related toxicity . The present trial , CYCLOPS , aim reduce cumulative exposure immunosuppressive drug administer cyclophosphamide ( CYC ) intermittent pulse . The potential benefit use CYC way AASV demonstrate preliminary , small study . Patients previously untreated AASV , “ generalise ” , life threatening , disease renal involvement , randomise either continuous oral CYC intermittent pulse CYC . CYC continue three month remission achieve , minimum CYC total duration six month maximum duration twelve month ; limb receive maintenance regimen azathioprine prednisolone . The study last 18 month . The primary end-point disease-free period , take period time remission relapse study end ; secondary end-points adverse effect , cumulative damage immunosuppressive drug exposure . 160 patient require .</detailed_description>
	<mesh_term>Vasculitis</mesh_term>
	<mesh_term>Granulomatosis Polyangiitis</mesh_term>
	<mesh_term>Systemic Vasculitis</mesh_term>
	<mesh_term>Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis</mesh_term>
	<mesh_term>Microscopic Polyangiitis</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<criteria>1 . A new diagnosis WG , MP renallimited vasculitis ( RLV ) ( appendix 5 ) . Patients previously treat cytotoxic drug permit . 2 . Renal involvement attributable active WG , MP RLV least one following : elevate serum creatinine 150 500 umol/l . biopsy demonstrate necrotizing glomerulonephritis . red cell cast . haematuria &gt; 30 red blood cells/high power field proteinuria &gt; 1g/24hr . 3 . ANCA positivity confirmatory histology ( appendix 5 ) . ANCA positivity require typical CANCA pattern indirect immunofluorescence ( IIF ) , ( preferably confirm antiPR3 ELISA ) , presence PR3ANCA MPOANCA determine ELISA , PANCA require confirmation antiMPO ELISA [ 6 ] . ( Central review ANCA serology histology perform ) . 4 . Age 1880 year . 1 . More two week treatment cyclophosphamide ( CYC ) cytotoxic drug within previous year oral corticosteroid ( OCS ) 4 week . If patient receive &gt; 1.0g methylprednisolone prior study start , discuss trial coordinator . 2 . Coexistence another multisystem autoimmune disease , e.g . SLE . 3 . Hepatitis Be antigen positive Hepatitis C antibody positive . 4 . Known HIV positivity ( HIV test requirement trial ) . 5 . Serum creatinine &gt; 500umol/l ( consider MEPEX trial ) . 6 . Immediately lifethreatening organ manifestation ( e.g . lung haemorrhage dialysis dependence ) . 7 . Previous malignancy ( usually exclude unless agree trial coordinator ) . 8 . Pregnancy inadequate contraception female . 9 . AntiGBM antibody positivity .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2007</verification_date>
	<keyword>Vasculitis</keyword>
	<keyword>ANCA</keyword>
	<keyword>Wegener 's granulomatosis</keyword>
	<keyword>Renal vasculitis</keyword>
	<keyword>Cyclophosphamide</keyword>
</DOC>